Objective To observe the value of advanced patient motion correction(APMC)technology for improving imaging quality of low-dose pediatric chest CT.Methods Ninety-six children who received low-dose chest CT scan were retrospectively enrolled.CT images were reconstructed using full reconstruction technique(FULL)or APMC for both lung window and mediastinal window.Then the imaging qualities were subjectively evaluated according to image clarity,degree of motion artifacts,sharpness of structural edges and overall quality.The indexes of objective evaluation of imaging quality included the mean CT values of unit density pixel within ROI on lung window and mediastinal window,the standard deviation of CT values(SDCT)representing image noise,as well as signal-to-noise ratio(SNR).Sobel operator edge detection was performed on images,recording the mean gray level(G)and the standard deviation of gray value in Sobel(SDsobel)within ROI.Comparisons were made between FULL reconstruction and corrected images with APMC reconstruction in terms of subjective and objective evaluations,as well as parameters obtained from Sobel output images.Results Compared to FULL reconstruction,APMC corrected images showed reduced motion artifacts,improved edge structure sharpness and enhanced overall image quality(all P＜0.05),while there was no significant difference of image clarity(P＞0.05).Meanwhile,with APMC reconstructions,the mean CT values,SDCT on lung window and SDCT on mediastinal window increased(all P＜0.05),but there was no significant difference for the mean CT values on mediastinal window(P＞0.05),and SNR on both lung window and mediastinal window decreased(both P＜0.05).Besides,for Sobel output images,compared to FULL reconstruction,APMC reconstruction had increased G and SDsobel on both lung window and mediastinal window(all P＜0.05).Conclusion APMC technology applicated in low-dose chest CT scan of children could effectively reduce motion artifacts,improve edge clarity and imaging quality,hence enhance diagnostic sensitivity.

Objective To observe the value of advanced patient motion correction(APMC)technology for improving imaging quality of low-dose pediatric chest CT.Methods Ninety-six children who received low-dose chest CT scan were retrospectively enrolled.CT images were reconstructed using full reconstruction technique(FULL)or APMC for both lung window and mediastinal window.Then the imaging qualities were subjectively evaluated according to image clarity,degree of motion artifacts,sharpness of structural edges and overall quality.The indexes of objective evaluation of imaging quality included the mean CT values of unit density pixel within ROI on lung window and mediastinal window,the standard deviation of CT values(SDCT)representing image noise,as well as signal-to-noise ratio(SNR).Sobel operator edge detection was performed on images,recording the mean gray level(G)and the standard deviation of gray value in Sobel(SDsobel)within ROI.Comparisons were made between FULL reconstruction and corrected images with APMC reconstruction in terms of subjective and objective evaluations,as well as parameters obtained from Sobel output images.Results Compared to FULL reconstruction,APMC corrected images showed reduced motion artifacts,improved edge structure sharpness and enhanced overall image quality(all P＜0.05),while there was no significant difference of image clarity(P＞0.05).Meanwhile,with APMC reconstructions,the mean CT values,SDCT on lung window and SDCT on mediastinal window increased(all P＜0.05),but there was no significant difference for the mean CT values on mediastinal window(P＞0.05),and SNR on both lung window and mediastinal window decreased(both P＜0.05).Besides,for Sobel output images,compared to FULL reconstruction,APMC reconstruction had increased G and SDsobel on both lung window and mediastinal window(all P＜0.05).Conclusion APMC technology applicated in low-dose chest CT scan of children could effectively reduce motion artifacts,improve edge clarity and imaging quality,hence enhance diagnostic sensitivity.

Objective:To explore the safety of azivudine tablets in the treatment of moderate coronavirus disease 2019 (COVID-19).Methods:Clinical data of adult COVID-19 patients who were hospitalized and treated with azivudine tablets at Xinglin Branch, the First Affiliated Hospital of Xiamen University from August 18 to September 18, 2022 were collected. The incidence, clinical manifestations, severity, and outcome of adverse reactions during treatment were analyzed descriptively and statistically.Results:A total of 117 patients were entered in the analysis, including 68 males (58.1%) and 49 females (41.9%); the age ranged from 18 to 76 years, with a median age of 44 years. The course of COVID-19 before taking azivudine tablets ranged from 2 to 25 days, with an average time of 13 days. Azivudine tablets were applicated for 2-14 days with an average time of 8 days. Among 117 patients, 10 patients (8.5%) had adverse reactions during taking azivudine tablets, including 5 patients with gastrointestinal reactions (2 had nausea, 2 had diarrhea, and 1 had abdominal distension), 2 patients with liver dysfunction and 2 patients with dizziness, 1 patient with elevated serum triglyceride level, and 1 with fatigue. Of them, one patient had 2 times of adverse reactions, which manifested as dizziness and abdominal distension. All patients recovered after discontinuation of azivudine tablets and/or symptomatic treatments. The severity of adverse reactions was grade 1 in 7 patients and grade 2 in 3 patients, and no grade 3 and above serious adverse reactions occurred. All adverse reactions observed in the study had been recorded in the drug label, and no new adverse reactions were found.Conclusions:Azivudine tablets is safe and well tolerated in the treatment of moderate COVID-19. The common adverse reactions were gastrointestinal reactions, abnormal liver function, and dizziness.

Objective:To explore the safety of azivudine tablets in the treatment of moderate coronavirus disease 2019 (COVID-19).Methods:Clinical data of adult COVID-19 patients who were hospitalized and treated with azivudine tablets at Xinglin Branch, the First Affiliated Hospital of Xiamen University from August 18 to September 18, 2022 were collected. The incidence, clinical manifestations, severity, and outcome of adverse reactions during treatment were analyzed descriptively and statistically.Results:A total of 117 patients were entered in the analysis, including 68 males (58.1%) and 49 females (41.9%); the age ranged from 18 to 76 years, with a median age of 44 years. The course of COVID-19 before taking azivudine tablets ranged from 2 to 25 days, with an average time of 13 days. Azivudine tablets were applicated for 2-14 days with an average time of 8 days. Among 117 patients, 10 patients (8.5%) had adverse reactions during taking azivudine tablets, including 5 patients with gastrointestinal reactions (2 had nausea, 2 had diarrhea, and 1 had abdominal distension), 2 patients with liver dysfunction and 2 patients with dizziness, 1 patient with elevated serum triglyceride level, and 1 with fatigue. Of them, one patient had 2 times of adverse reactions, which manifested as dizziness and abdominal distension. All patients recovered after discontinuation of azivudine tablets and/or symptomatic treatments. The severity of adverse reactions was grade 1 in 7 patients and grade 2 in 3 patients, and no grade 3 and above serious adverse reactions occurred. All adverse reactions observed in the study had been recorded in the drug label, and no new adverse reactions were found.Conclusions:Azivudine tablets is safe and well tolerated in the treatment of moderate COVID-19. The common adverse reactions were gastrointestinal reactions, abnormal liver function, and dizziness.

Objective To analyze the changes of CD4⁺ T cell numbers at different periods of antiviral therapy in HIV-infected and AIDS patients (HIV/AIDS) in Yichang City. Methods The relevant information was retrieved from the National AIDS Comprehensive Prevention Information System-Antiretroviral Treatment Management Database. Changes in the number of CD4⁺ T cells were analyzed in HIV/AIDS patients who started receiving highly active antiretroviral therapy (HAART) and continued the treatment for 3 years from January 1, 2003 to December 31, 2017 in Yichang. Results The number of CD4⁺T lymphocytes in 550 HIV/AIDS cases increased significantly at various time points within 3 years after treatment, and increased with the increase of treatment time（F=100.20，P<0.001）. The CD4+T cell counts of different baseline level groups were statistically different before and after treatment（F=8.57，P<0.01）. The CD4+ T cell counts of patients who started treatment at age of 15-30 years old increased faster than those who started treatment at age of over 30 years old（F=1.27，P<0.05）. Conclusion HAART has a significant effect on the increase of CD4+T cells, and the early treatment is more effective. Early detection, diagnosis and treatment should be promoted, and anti-viral treatment should be actively carried out.

Objective To evaluate the feasibility of PerkinElmer Genetic Screening Processor(GSP) in the application of newborn screening for congenital hypothyroidism (CH) and congenital adrenal hyperplasia (CAH) by detecting thyroid-stimulating hormone (TSH) and 17-OH-progesterone(17-OHP).Methods The dried-blood spots specimens from Centers for Disease Control and Prevention(CDC) and the quality control in the reagent kit were detected and the accuracy,precision and linearity were calculated.A total of 1 012 samples of TSH(60 of positive and 952 negative samples) and 991 samples of 17-0HP(34 positive and 957 negative samples)were detected.The initial cut-off value was determined by ROC curve determined.The consistency between the results from GSP and clinical diagnosis was analyzed.Results The average of within-run coefficient of variation(CV) of TSH and 17-OHP were 6.69％ to 12.6％ and 7.52％ to 9.29％,and the average of between-run CV were 6.91％ to 10.96％ and 6.86％ to 12.36％,respectively.The average of bias of TSH and 170HP were-14.28％ to-0.74％ and-0.45％ to 12.54％.The linearity of GSP detection was fine.The initial cut-off values were 23.43 U/mL(TSH) and 21.42 ng/mL(17-OHP).The sensitivity of GSP detection was 100％ and the specificity of TSH and 17-OHP were 98.11％ and 99.58 ％ respectively.The results of GSP detection showed good consistency with clinical diagnosis.Conclusion As the first real automatic fluorescence immunoassay analyzer,GSP could be used in routine clinical diagnosis for CH and CAH.

This article was aimed to study the Uygur medicine Hyssopus officinalis L. on the balance of Th1/Th2 and Th17/Treg of chronic obstructive pulmonary disease (COPD) mice in order to explore the mechanism of its treatment of COPD. The pre-fumigation method was copied to establish a mouse model of COPD. Mice were ran-domly divided into the normal control group, saline group and water extract of H. officinalis L. high, middle and low dose group. The level of serum IFN-λ, IL-4, IL-17 and IL-10 were detected with ELISA. The results showed that compared with the normal control group, the serum IL-4 and IL-17 level of the COPD model group were significantly higher (P < 0.05), and the serum IFN-λ and IL-10 level were significantly lower (P < 0.05). After drug intervention, the IL-4 and IL-17 level were significantly lower, and the IFN-λ and IL-10 level were significantly increased compared with the model group. The correlation analysis showed that the IFN-λ, IL-4, IL-17 and IL-10 were negatively related. It was concluded that H. officinalis L. played a certain role on correct-ing imbalances of Th1/Th2 and Th17/Treg.

Objective: To investigate the biological phenotype and cell cycle distribution characteristics of nasal and/or nasopharyngeal epithelia of TgN(p53mt-LMP1)/HT mice.Methods: The biological phenotype changes(mainly the incidence of precancerous lesion) in nasal and nasopharyngeal epithelial tissues of the generation G4 of TgN(p53mt-LMP1)/HT mice aged 5,11,15 and 18 months were determined by H-E staining,and the cell cycle characteristics of nasal and nasopharyngeal epithelia detected by flow cytometry(FCM).Results: The incidences of precancerous lesion in the nasal and nasopharyngeal epithelia were 0,50%,60% and 75% respectively in the 5,11,15 and 18 mos groups of the positively expressed transgenic mice,and 0 in the four age groups of the negatively expressed ones.Compared with the negatively expressed transgenic mice,the number of nasal or nasopharyngeal epithelial cells was markedly decreased in the G0/G1 phase,but obviously increased in the S and G2/M phases,with the proliferation index(PI) significantly enhanced(P

OBJECTIVETo develop and identify the monoclonal antibodies (mAb) against c-erbB-2 p185 intracellular domain for detection of c-erbB-2 protein overexpression in breast tumor cells.

METHODSBALB/C mice were immunized with a synthesized p185 peptide of intracellular domain. The biological characteristics and immunoactivities were identified by different techniques.

RESULTSThree hybridoma cell strains secreting mAbs to c-erbB-2 protein were established and one of the mAbs, No. 035-E61 was tested for c-erbB-2 protein immunostaining on 39 breast carcinoma sections, 30 breast fibroadenoma sections and 16 sections from various normal organs. The results showed that the positive detection frequency of protein expression was 26% (10/39) in breast cancer, none (0/30) in fibroadenoma and 3 sections from normal organs were positively stained. The consistency between the 035-E61 and the DAKO reagent approved by FDA was 74%.

CONCLUSIONSNo. 035-E61 mAb can specifically recognize the p185 intracellular domain and may be useful in guiding clinical Herceptin treatment.

Animals ; Antibodies, Monoclonal ; immunology ; Antibody Specificity ; Binding Sites ; immunology ; Breast Neoplasms ; immunology ; pathology ; Female ; Fibroadenoma ; immunology ; pathology ; Humans ; Immunoglobulin G ; immunology ; Immunohistochemistry ; Mice ; Mice, Inbred BALB C ; Receptor, ErbB-2 ; immunology ; Tumor Cells, Cultured